Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection
NCT: NCT07059819 · ENROLLING_BY_INVITATION
Brief Summary
Human papillomavirus(HPV) infect epithelial cells and have the capacity to stimulate cell abnormal hyperplasia, especially by those high-risk HPV types. HPV vaccine primarily targeting HPV6/11/16/18 has been available and makes it possible to prevent cervical cancer. However, a large population was left unvaccinated, specifically for those aged ones. In clinic, patients harboring high-risk HPV is quite prevalent in China or other developing nations. Removing the virus and prevention of malignant transformation is required. Mild local Hyperthermia with a certain temperature range has been successfully used in the treatment of some diseases. It has been utilized in the treatment of some neoplasm, fungal and HPV infections. Investigators' study found that local hyperthermia at 44°C could cleared HPV in more than half of the patients with HR-HPV in cervical area. So the purpose of the study is to evaluate the effective of local hyperthermia in the treatment of cervical intraepithelial neoplasias grade I and II after 3 months. Appropriate control arms were designed for different conditions.
Frequently Asked Questions
What is Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection?
Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection is a clinical trial registered under NCT07059819. Current status: ENROLLING_BY_INVITATION.
What is the status of NCT07059819?
The current status of NCT07059819 (Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection) is: ENROLLING_BY_INVITATION.
When did Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection start?
Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection started on 2024-11-02.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.